ClinicalTrials.gg
RecruitingNCT07310758Updated Dec 30, 2025

Contrast-enhanced Ultrasound for Sentinel Node Detection

A Phase 2/3 interventional study of Sonazoid in Melanoma, Breast Cancer and Head & Neck Cancer, sponsored by The Netherlands Cancer Institute. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-30.

Sponsored by The Netherlands Cancer Institute · Phase 2/3, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
91
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Melanoma by The Netherlands Cancer Institute — 4 open to participants now, 7 under way, 2 of them phase 3. Melanoma · The Netherlands Cancer Institute.

Planned enrollment
5th of 14
91 · median 35
Started
2025
the only one that year
Phase 2/3
Only one
of the 14
Registered
14th of 14
by date

Among the 14 studies in Melanoma by The Netherlands Cancer Institute, this one is the 5th largest by planned enrollment, is the only one that started in 2025, is the only one in phase 2/3, and was the 14th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.

Browse Melanoma studies →

Open to participants now

4 of the 14 studies in Melanoma by The Netherlands Cancer Institute are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Melanoma by The Netherlands Cancer Institute, or all of them as a file.
02

Study summary

This is a prospective single-center interventional non-inferiority study where subjects are participating for one day for patients 18 years or older with melanoma, breast cancer or head \& neck cancer (including melanoma of head and neck area) and scheduled for a surgical SN procedure in the NKI-AvL without any contra-indication for Sonazoid contrast agent, such as an allergy to eggs or egg products. The primary objective is to assess the sensitivity of CEUS for intra-operative SN localization compared to the gold standard (99mTc nanocolloid). Secondary objectives are the specificity of CEUS for intra-operative SN localization, the time required to localize the SNs using CEUS and intraoperative usability of the CEUS-system. The primary endpoint is the sensitivity of the CEUS SN localization method. The conventional gamma probe will be used as ground truth comparison.

03

Conditions studied

  • Melanoma
  • Breast Cancer
  • Head & Neck Cancer

Keywords

  • contrast-enhanced ultrasound
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 years or older
  • Patient has been diagnosed with cancer in the skin (melanoma), breast or head \& neck (including melanoma of head and neck area)
  • In case of a melanoma: it should be located in the limbs or head and neck area
  • Scheduled for a surgical SN procedure at the NKI-AvL
  • Patient provides written

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Any known acute reaction to the study medication, such as eggs or egg products
  • Other for Sonazoid contrast agent, including arteriovenous cardiac or pulmonary shunt, serious coronary arterial disease and serious pulmonary disease
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
91 participants (estimated)

Study arms

  • Other
    Intra-operative Sonazoid injection

    Drug: Sonazoid

Interventions

  • Intradermal injection of the ultrasound contrast agent Sonazoid.

06

What researchers measure

Primary outcomes

  1. Sensitivity of the CEUS SN localization method

    To assess the sensitivity of CEUS for intra-operative SN localization compared to the gold standard (99mTc nanocolloid). Could CEUS replace the conventional radioactive technetium method?

    Time frame: 1 day

Secondary outcomes

  1. Specificity of the CEUS SN localization method

    Specificity of CEUS for intra-operative SN localization compared to the gold standard (99mTc nanocolloid)

    Time frame: 1 day

  2. Time in minutes

    Time required to localize the SNs using CEUS.

    Time frame: 1 day

  3. System-usability score (SUS) and questionnaire for the surgeon.

    Intraoperative usability of the CEUS-system.

    Time frame: 1 day

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Sep 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2025
First posted
Dec 30, 2025
StartActual
Sep 18, 2025
Primary completionEst.
Sep 18, 2026
CompletionEst.
Sep 18, 2026
Last update
Dec 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07310758
Collaborators
GE Healthcare
Responsible party
Sponsor
First posted
Dec 30, 2025
Start date
Sep 18, 2025
Primary completion
Sep 18, 2026 (estimated)
Completion
Sep 18, 2026 (estimated)
Last update
Dec 30, 2025

Study contacts

Marijn Hiep
Contact
ma.hiep@nki.nl
+31205121751
Quirijn Tummers
principal investigator · The Netherlands Cancer Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sonazoid

Start the discussion